Suzhou Fushilai Pharmaceutical Co., Ltd. (SHE:301258)

Market Cap	3.04B +38.1%
Revenue (ttm)	439.57M +6.4%
Net Income	75.96M +302.4%
EPS	0.84 +309.6%
Shares Out	89.68M
PE Ratio	40.30
Forward PE	n/a
Dividend	0.09 (0.28%)
Ex-Dividend Date	Jun 12, 2025

Volume	1,098,600
Average Volume	1,033,426
Open	32.70
Previous Close	32.80
Day's Range	32.50 - 33.98
52-Week Range	20.56 - 39.28
Beta	0.54
RSI	46.72
Earnings Date	Apr 23, 2026

About SHE:301258

Suzhou Fushilai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and health care raw materials in China and internationally. The company offers lipoic acid products comprising granular alpha lipoic acid, R-lipoic acid, r-lipoic acid tromethamine salt, and 6,8-dichlorooctanoic acid ethyl ester; l-carnosine; phosphatidylcholine products, which include glycerylphosphatidylcholine; and erelcoxib API, a nonst...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 524
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301258

Financial Performance

In 2024, SHE:301258's revenue was 429.47 million, a decrease of -12.23% compared to the previous year's 489.29 million. Earnings were 16.41 million, a decrease of -85.38%.